← Leaderboards
Jenny Zilberberg
Hackensack University Medical Center
$1,447,482
Attributed
$2,410,688
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $540.1K · FY2010–19$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,410,688 · 3
By mechanism
R33$1,240,733 · 1
R21$1,169,955 · 2
Top collaborators
- Woo Young Lee9 shared
Others in their field
Top investigators on “Malignant - Descriptor”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,073,740,423
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$245,977,428
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant - DescriptorCellsNeoplastic CellTumorMalignant NeoplasmsNeoplasm MetastasisBoneSerumPlasma CellsPharmaceutical PreparationsRelapseDrug ResistanceMultiple MyelomaAntibodiesBone MarrowEvaluationBone DevelopmentNovel TherapeuticsLesionMalignant Neoplasm Of ProstateOsteoblastsB Lymphoid MalignancyResistanceImplant
Grant awards (11)
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$218,834
R33 · FY2019 · CA · contact PI
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$118,189
R33 · FY2019 · CA · contact PI
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$389,121
R33 · FY2018 · CA · contact PI
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$121,845
R33 · FY2018 · CA · contact PI
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$29,161
R33 · FY2018 · CA · contact PI
Ex vivo culture platform validation for preservation of patient derived multiple myeloma cells$363,583
R33 · FY2017 · CA · contact PI
Microfluidic approach for the development of a three-dimensional bone marrow micr$133,331
R21 · FY2016 · CA · contact PI
Microfluidic approach for the development of a three-dimensional bone marrow micr$266,662
R21 · FY2015 · CA · contact PI
Microfluidic approach for the development of a three-dimensional bone marrow micr$285,687
R21 · FY2014 · CA · contact PI
Stable shRNA-mediated gene silencing of the beta 7 integrin to ameliorate graft-v$220,125
R21 · FY2011 · HL · contact PI
Stable shRNA-mediated gene silencing of the beta 7 integrin to ameliorate graft-v$264,150
R21 · FY2010 · HL · contact PI